Background/Aim Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the
central nervous system. Effector T helper cells, mainly Th1 and Th17, cytotoxic T-cells, B …

Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …

Both genetic and environmental factors contribute to the aetiology of multiple sclerosis (MS).
More than 50 genomic regions have been associated with MS susceptibility and vitamin D …

Neurodegeneration is a critical determinant of disability in the inflammatory demyelinating
diseases of both the central nervous system and peripheral nervous system. Current …

Introduction: The understanding of the immunopathogenesis of multiple sclerosis (MS) has
expanded with more research into T-cell subtypes, cytokine contributors, B-cell participation …

Abstract Herpesviruses like Epstein-Barr virus, human herpesvirus (HHV)-6, HHV-1, VZV,
and human endogenous retroviruses, have an age-old clinical association with multiple …

Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple
sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals …

Objectives There are no data regarding the relationship between Helicobacter pylori
infection (Hp‐I) and clinically isolated syndrome (CIS) suggestive of multiple sclerosis. The …

Background Changes in the blood lymphocyte composition probably both mediate and
reflect the effects of natalizumab treatment in multiple sclerosis, with implications for …

Apolipoprotein D (Apo D) overexpression is a general finding across neurodegenerative
conditions so the role of this apolipoprotein in various neuropathologies such as multiple …